A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)

DOI: 10.1634/theoncologist.2018-0878

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text